Usual Entresto Dose for Heart Failure
The target maintenance dose of Entresto for adults with heart failure is 97/103 mg twice daily, starting from an initial dose of 49/51 mg twice daily and doubling after 2-4 weeks as tolerated. 1
Standard Dosing Protocol
For most adult patients with HFrEF:
- Starting dose: 49/51 mg orally twice daily 1
- Titration schedule: Double the dose after 2-4 weeks 1
- Target maintenance dose: 97/103 mg twice daily 1
This represents the FDA-approved dosing regimen that was used in the landmark clinical trials demonstrating mortality and morbidity benefits 1. The American College of Cardiology recommends ARNi (sacubitril/valsartan) as preferred over ACE inhibitors or ARBs in NYHA class II-III patients to further reduce morbidity and mortality 2.
Modified Starting Dose (Lower Initial Dose)
Reduce the starting dose to 24/26 mg twice daily in these specific situations: 1
- Patients not currently taking an ACE inhibitor or ARB
- Patients previously taking low doses of ACE inhibitors or ARBs
- Patients with severe renal impairment
- Patients with moderate hepatic impairment
After initiating at the lower dose, increase every 2-4 weeks following the standard escalation pathway (24/26 mg → 49/51 mg → 97/103 mg) 1.
Critical Switching Considerations
When transitioning from an ACE inhibitor: Allow a mandatory 36-hour washout period between the last ACE inhibitor dose and the first Entresto dose to avoid angioedema risk 1. This is a contraindication, not merely a precaution.
Real-World Dosing Patterns vs. Target Doses
While the target dose is 97/103 mg twice daily, real-world data reveals significant gaps in dose optimization:
- Only 17-27% of patients achieve target dose within 4-6 months in clinical practice 3, 4
- Approximately 41% remain on 49/51 mg twice daily and 32% on 24/26 mg twice daily at 6 months 4
- However, dose matters for outcomes: Patients on 24/26 mg twice daily have significantly higher mortality (HR 2.56) and HF hospitalization rates (HR 1.79) compared to those achieving 97/103 mg twice daily 5
The American College of Cardiology emphasizes continuing uptitration even if symptoms improve at lower doses, as clinical trials demonstrated benefits at target doses 2. This is a critical pitfall to avoid—do not accept clinical improvement at subtherapeutic doses as sufficient.
Blood Pressure Considerations
Low blood pressure should not prevent Entresto initiation: 6
- Even patients with SBP 100-110 mmHg can achieve target dosing in approximately 73% of cases 6
- Gradual uptitration over 6 weeks (rather than 3 weeks) improves success rates in patients with lower baseline blood pressure 6
- Hypotension occurs more frequently in lower SBP patients but is manageable with slower titration 6
Dose-Dependent Benefits
Higher doses provide superior outcomes: 5, 7
- NT-proBNP reduction is significantly greater with higher doses (pooled effect size -667.24, p=0.04) 7
- All-cause mortality decreases progressively: 29.6% at 24/26 mg, 17.6% at 49/51 mg, and 9.3% at 97/103 mg 5
- HF hospitalization rates similarly decline with dose escalation 5
Long-Term Maintenance
Once target dose is achieved: 8, 9
- The medication is well-tolerated long-term with mean exposure rates of 98.9% 8
- Benefits persist across all age groups, including patients ≥90 years old 9
- Cardiovascular hospitalization rates decrease significantly even in elderly populations (from 0.78 to 0.42 events/year in patients ≥90 years) 9
Common Pitfalls to Avoid
The American College of Cardiology specifically warns against: 2
- Failing to uptitrate to target doses used in clinical trials
- Discontinuing medications when LVEF improves
- Delaying initiation due to concerns about polypharmacy
In practice, the main barriers to achieving target dose include: 4
- Slower uptitration than trial protocols (54.7% of cases)
- Systolic blood pressure concerns (25.3%)
- Patient non-compliance (4%)
The key to success is systematic, protocol-driven uptitration every 2-4 weeks with close monitoring, rather than accepting symptomatic improvement at suboptimal doses.